Coave Therapeutics announces Positive 12-months data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in patients with retinitis pigmentosa caused by bi-allelic mutations in PDE6b
Seroba portfolio company, Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, today announces the positive 12-month results from its Phase I/II trial evaluating the safety and efficacy of its innovative gene therapy, CTx-PDE6b, for retinitis pigmentosa (RP) caused by bi-allelic mutations in the PDE6B gene (PDE6b RP). …